Copyright
©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 381-389
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Table 9 Insulin dose (U/d) before and after autologous bone marrow derived stem cell therapy in Group III
| Patient | Baseline | 3 mo | 6 mo | 12 mo | 18 mo |
| 1 | 53 | 48 | 36 | 27 | 18 |
| 2 | 47 | 34 | 15 | 12 | - |
| 3 | 51 | 25 | Nil | Nil | - |
| 4 | 75 | 78 | 86 | 70 | - |
| 5 | 26 | 26 | 18 | 24 | - |
| 6 | 25 | 20 | 18 | - | - |
| 7 | 38 | 32 | 30 | - | - |
| Mean ± SE | 45 ± 7 | 38 ± 8 | 34 ± 11 | ||
| P value | 0.087 | 0.137 |
- Citation: Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, Khandelwal N. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. World J Diabetes 2017; 8(7): 381-389
- URL: https://www.wjgnet.com/1948-9358/full/v8/i7/381.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i7.381